Literature DB >> 14512790

Chromosomal imbalances in primary and metastatic melanomas: over-representation of essential telomerase genes.

Christine Pirker1, Klaus Holzmann, Sabine Spiegl-Kreinecker, Leonilla Elbling, Christiane Thallinger, Hubert Pehamberger, Michael Micksche, Walter Berger.   

Abstract

Comparative genomic hybridization was used to map copy number abnormalities in 48 short-term cell cultures established from different stages and types of human melanoma. A variety of random and non-random chromosomal alterations were detected, with gains within chromosomes 20q, 7q, 7p, 20p, 6p and 17q and losses in 9p, 10q, 6q, 10p, 4q, and 11q being the most common observations. In addition, several other chromosomal loci were over- or under-represented in subgroups of melanomas. For example, sequences on 3q26 were over-represented in 33% and on 5p15.33 in 27% of cell cultures, reaching the level of amplification in 12% and 22%, respectively. These regions harbour the two essential genes for the enzyme telomerase: the telomerase reverse transcriptase gene (hTERT) on 5p15.33 and the telomerase RNA component gene (hTERC) on 3q26. Using fluorescence in situ hybridization and Southern blot analysis, both genes were shown to be over-represented or amplified in several melanomas. Interestingly, hTERT amplification was abundant in superficial spreading primary melanomas, subcutaneous metastases and malignant effusion-derived cells, but completely absent or very rare in primary nodular melanomas as well as brain, bone and lymph node metastases. Several chromosomes or chromosomal regions harbouring telomerase-suppressing activities (3p, 4, 6 and 10p) were frequently under-represented in melanomas. Our data suggest that genetic alterations at several chromosomal loci might facilitate activation of telomerase during the development of cutaneous malignant melanoma.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14512790     DOI: 10.1097/00008390-200310000-00007

Source DB:  PubMed          Journal:  Melanoma Res        ISSN: 0960-8931            Impact factor:   3.599


  28 in total

1.  Seven novel and stable translocations associated with oncogenic gene expression in malignant melanoma.

Authors:  Ichiro Okamoto; Christine Pirker; Martin Bilban; Walter Berger; Doris Losert; Christine Marosi; Oskar A Haas; Klaus Wolff; Hubert Pehamberger
Journal:  Neoplasia       Date:  2005-04       Impact factor: 5.715

2.  Fibroblast growth factor receptors as therapeutic targets in human melanoma: synergism with BRAF inhibition.

Authors:  Thomas Metzner; Alexandra Bedeir; Gerlinde Held; Barbara Peter-Vörösmarty; Sara Ghassemi; Christine Heinzle; Sabine Spiegl-Kreinecker; Brigitte Marian; Klaus Holzmann; Bettina Grasl-Kraupp; Christine Pirker; Michael Micksche; Walter Berger; Petra Heffeter; Michael Grusch
Journal:  J Invest Dermatol       Date:  2011-07-14       Impact factor: 8.551

3.  Quantification of hTERT splice variants in melanoma by SYBR green real-time polymerase chain reaction indicates a negative regulatory role for the beta deletion variant.

Authors:  Lisa F Lincz; Lisa-Maree Mudge; Fiona E Scorgie; Jennette A Sakoff; Christopher S Hamilton; Michael Seldon
Journal:  Neoplasia       Date:  2008-10       Impact factor: 5.715

Review 4.  Chromatin and epigenetic regulation of the telomerase reverse transcriptase gene.

Authors:  Jiyue Zhu; Yuanjun Zhao; Shuwen Wang
Journal:  Protein Cell       Date:  2010-02-07       Impact factor: 14.870

5.  Ligand-activated BMP signaling inhibits cell differentiation and death to promote melanoma.

Authors:  Arvind M Venkatesan; Rajesh Vyas; Alec K Gramann; Karen Dresser; Sharvari Gujja; Sanchita Bhatnagar; Sagar Chhangawala; Camilla Borges Ferreira Gomes; Hualin Simon Xi; Christine G Lian; Yariv Houvras; Yvonne J K Edwards; April Deng; Michael Green; Craig J Ceol
Journal:  J Clin Invest       Date:  2017-12-04       Impact factor: 14.808

6.  Frequent somatic mutations of the telomerase reverse transcriptase promoter in ovarian clear cell carcinoma but not in other major types of gynaecological malignancy.

Authors:  Ren-Chin Wu; Ayse Ayhan; Daichi Maeda; Kyu-Rae Kim; Blaise A Clarke; Patricia Shaw; Michael Herman Chui; Barry Rosen; Ie-Ming Shih; Tian-Li Wang
Journal:  J Pathol       Date:  2014-03       Impact factor: 7.996

7.  Highly recurrent TERT promoter mutations in human melanoma.

Authors:  Franklin W Huang; Eran Hodis; Mary Jue Xu; Gregory V Kryukov; Lynda Chin; Levi A Garraway
Journal:  Science       Date:  2013-01-24       Impact factor: 47.728

8.  Survivin repression by p53, Rb and E2F2 in normal human melanocytes.

Authors:  Deepak Raj; Tong Liu; George Samadashwily; Fengzhi Li; Douglas Grossman
Journal:  Carcinogenesis       Date:  2007-10-04       Impact factor: 4.944

9.  Oral and dental phenotype of dyskeratosis congenita.

Authors:  J C Atkinson; K E Harvey; D L Domingo; M I Trujillo; J P Guadagnini; S Gollins; N Giri; T C Hart; B P Alter
Journal:  Oral Dis       Date:  2008-07       Impact factor: 3.511

10.  Rearrangement of upstream sequences of the hTERT gene during cellular immortalization.

Authors:  Yuanjun Zhao; Shuwen Wang; Evgenya Y Popova; Sergei A Grigoryev; Jiyue Zhu
Journal:  Genes Chromosomes Cancer       Date:  2009-11       Impact factor: 5.006

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.